Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyperstimulation for IVF with ICSI using GnRH antagonist

被引：0
|
作者：
Mustafa Bahceci
Ulun Ulug
机构：
[1] Bahceci Women Health Care Center,
[2] Bahceci Women Health Care Center and German Hospital in Istanbul,undefined
来源：
Journal of Assisted Reproduction and Genetics | 2008年 / 25卷
关键词：
Progesterone; Vaginal; Intramuscular; IVF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：499 / 502
页数：3
相关论文
共 50 条
  • [41] The effect of luteinizing hormone changes in GnRH antagonist protocol on the outcome of controlled ovarian hyperstimulation and embryo transfer
    Zhou, Jing-Shuang
    Chen, Jian-Hong
    Tang, Fei-Fei
    Ou, Jian-Ping
    Tao, Xin
    Cai, Liu-Hong
    BMC PREGNANCY AND CHILDBIRTH, 2023, 23 (01)
  • [42] Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols:: a matched study
    Del Gadillo, JCB
    Siebzehnrübl, E
    Dittrich, R
    Wildt, L
    Lang, N
    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2002, 102 (02): : 179 - 183
  • [43] Do IVF patients prefer the rectal route to the vaginal for luteal phase progesterone administration? - a cohort study
    Jensen, M. Brix
    Mikkelsen, A.
    Kyndi, M.
    Humaidan, P.
    Alsbjerg, B.
    HUMAN REPRODUCTION, 2023, 38
  • [44] Administration of gonadotropin-releasing hormone agonist during the luteal phase of GnRH-antagonist IVF cycles
    Hugues, J. N.
    Cedrin-Durnerin, I.
    Bstandig, B.
    Theron-Gerard, L.
    Grange, D.
    Laffy, A.
    Clement, P.
    Hamidi, J.
    Sifer, C.
    Poncelet, C.
    HUMAN REPRODUCTION, 2006, 21 : I3 - I3
  • [45] GnRH agonist administration in the luteal phase does not increase clinical pregnancy or implantation rates following ICSI-ET in GnRH agonist or antagonist treated ovarian stimulation cycles
    Ata, B.
    Yakin, K.
    Balaban, B.
    Urman, B.
    FERTILITY AND STERILITY, 2007, 88 : S163 - S163
  • [46] Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles
    Tesarik, Jan
    Hazout, Andre
    Mendoza-Tesarik, Raquel
    Mendoza, Nicolas
    Mendoza, Carmen
    HUMAN REPRODUCTION, 2006, 21 (10) : 2572 - 2579
  • [47] Administration effects of single-dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta-analysis of randomized controlled trials
    Song, Mengling
    Liu, Chunlian
    Hu, Rong
    Wang, Feimiao
    Huo, Zhenghao
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 19 (01) : 786 - 796
  • [48] Pregnancy rates and risk of ovarian hyperstimulation syndrome (OHSS) in a fixed GnRH-antagonist versus GnRH-agonist protocol: randomized controlled trial including 1099 first IVF/ICSI cycles
    Toftager, M.
    Bogstad, J.
    Lossl, K.
    Praetorius, L.
    Zedeler, A.
    Bryndorf, T.
    Nilas, L.
    Pinborg, A.
    HUMAN REPRODUCTION, 2015, 30 : 94 - 95
  • [49] A randomized prospective study comparing the use of a standard GnRH antagonist versus a 'long' antagonist protocol for controlled ovarian hyperstimulation prior to IVF.
    Weissman, A
    Biran, G
    Ravhon, A
    Nahum, H
    Glezerman, M
    Levran, D
    FERTILITY AND STERILITY, 2005, 84 : S309 - S309
  • [50] Efficacy and safety of gonadotropin releasing hormone (GnRH) antagonist administration in infertile women during controlled ovarian hyperstimulation
    Cattani, R
    Cela, V
    Cristello, F
    Matteucci, C
    Valentino, V
    Curcio, C
    Monti, M
    Tartaglia, ML
    Vitè, A
    Taponeco, F
    Genazzani, AR
    RECENT RESEARCH IN GYNECOLOGICAL ENDOCRINOLOGY, 2001, : 107 - 110
12345